NASDAQ:ADXS

Advaxis Stock Forecast, Price & News

Add

Compare

Today's Range: N/A
50-Day Range: N/A
52-Week Range: N/A

Volume: 1.31 million shs
Average Volume: 607,996 shs
Market Capitalization: $9.03 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: N/A

Advaxis MarketRank™ Forecast

Analyst Rating: N/A
Upside/Downside: N/A
Short Interest: N/A
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: 0.00
Based on 2 Articles This Week
Insider Trading: N/A
Proj. Earnings Growth: N/A

Overall MarketRank^™

MarketRank is calculated as 30% analysis score, 20% valuation score, 10% short interest score, 10% dividend score, 10% sustainability score, 10% news and social score, and 10% insider trading score.

0.33 out of 5 stars

0.0 Analyst's Opinion

Consensus Rating
There is not enough analysis data for Advaxis.

0.0 Short Interest

Short Interest
There is no current short interest data available for ADXS.

0.0 Dividend Strength

Dividend Yield
Advaxis does not currently pay a dividend.
Dividend Growth
Advaxis does not have a long track record of dividend growth.

0.0 Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for ADXS.

1.7 News and Social Media Coverage

News Sentiment
Advaxis has a news sentiment score of 0.00. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.79 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 2 news articles for Advaxis this week, compared to 1 article on an average week.
Search Interest
Only 2 people have searched for ADXS on MarketBeat in the last 30 days. This is a decrease of -75% compared to the previous 30 days.
MarketBeat Follows
2 people have added Advaxis to their MarketBeat watchlist in the last 30 days.

0.0 Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Advaxis insiders have not sold or bought any company stock.
Percentage Held by Insiders
Only 0.30% of the stock of Advaxis is held by insiders.
Percentage Held by Institutions
Only 0.06% of the stock of Advaxis is held by institutions.

0.0 Earnings and Valuation

Price to Earnings Ratio vs. the Market
The P/E ratio of Advaxis is -0.62, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Advaxis is -0.62, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

See Top Rated MarketRank™ Stocks Here

Receive ADXS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Advaxis and its competitors with MarketBeat's FREE daily newsletter.

About Advaxis (NASDAQ:ADXS) Stock

Advaxis, Inc., a clinical-stage biotechnology company, focuses on the discovery, development, and commercialization of proprietary Listeria monocytogenes (Lm) technology antigen delivery products in the United States. The company is developing ADXS-PSA, which is in Phase 2 clinical trials for the treatment of metastatic prostate cancer; ADXS-503 that is in Phase 1/2 clinical trials for the treatment of non-small cell lung cancer; and ADXS-504 for the treatment of prostate cancer. It is also conducting clinical studies of Lm Technology immunotherapies in the following areas of disease focused hotspot/off-the-shelf neoantigen-directed therapies; human papilloma virus-associated cancers; and prostate cancer. The company has collaborations and partnerships with Merck & Co., Inc.; OS Therapies, LLC; Aratana Therapeutics Inc.; Biocon Limited; Global BioPharma Inc.; Knight Therapeutics Inc; and others. Advaxis, Inc. was founded in 2002 and is based in Monmouth Junction, New Jersey.

June 29, 2022 | tmcnet.com

Advaxis Updates on the Phase 1 Clinical Trial of ADXS-504 for the Treatment of Early Prostate Cancer

June 27, 2022 | americanbankingnews.com

Advaxis (NASDAQ:ADXS) Coverage Initiated at StockNews.com

June 9, 2022 | americanbankingnews.com

Advaxis (NASDAQ:ADXS) Now Covered by Analysts at StockNews.com

See More Headlines

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Pharmaceutical preparations
Sub-Industry: N/A
Sector: Medical
Current Symbol: NASDAQ:ADXS
CUSIP: N/A
CIK: 1100397
Web: www.advaxis.com
Phone: 609 452 9813
Fax: 609-452-9818
Employees: N/A
Year Founded: N/A

Company Calendar

Today: 7/03/2022
Fiscal Year End: 10/31/2022

Profitability

EPS (Most Recent Fiscal Year): ($0.10)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-17.86 million
Net Margins: N/A
Pretax Margin: -873.85%
Return on Equity: -42.66%
Return on Assets: -36.09%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 11.59
Quick Ratio: 11.59

Sales & Book Value

Annual Sales: $3.24 million
Price / Sales: 0.00
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $0.27 per share
Price / Book: N/A

Miscellaneous

Outstanding Shares: 145,638,000
Free Float: 145,201,000
Market Cap: $9.03 million
Optionable: Not Optionable
Beta: 2.15

Advaxis Frequently Asked Questions

Who are Advaxis' key executives?: Advaxis' management team includes the following people:
Mr. Kenneth A. Berlin J.D., Pres, CEO & Director (Age 58, Pay $625.4k)
Mr. Igor Gitelman CPA, CPA, M.B.A., MBA, Chief Accounting Officer, Interim CFO & VP of Fin. (Age 46, Pay $297.87k)
Dr. Andres A. Gutierrez M.D., Ph.D., Exec. VP & Chief Medical Officer (Age 61, Pay $472.03k)
Who are some of Advaxis' key competitors?: Some companies that are related to Advaxis include NeuroSense Therapeutics (NRSN), ASLAN Pharmaceuticals (ASLN), Ceapro (CRPOF), Synaptogenix (SNPX), Galera Therapeutics (GRTX), BioVie (BIVI), Biofrontera (BFRI), Eledon Pharmaceuticals (ELDN), Angion Biomedica (ANGN), Oncorus (ONCR), Context Therapeutics (CNTX), Acura Pharmaceuticals (ACUR), NeuBase Therapeutics (NBSE), NuCana (NCNA) and Corbus Pharmaceuticals (CRBP).
View all of ADXS's competitors.

What other stocks do shareholders of Advaxis own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Advaxis investors own include Inovio Pharmaceuticals (INO), Madrigal Pharmaceuticals (MDGL), Merck & Co., Inc. (MRK), Anavex Life Sciences (AVXL), VistaGen Therapeutics (VTGN), Novavax (NVAX), (CELG), Highpower International (HPJ), OPKO Health (OPK) and Athersys (ATHX).
What is Advaxis' stock symbol?: Advaxis trades on the NASDAQ under the ticker symbol "ADXS."
How do I buy shares of Advaxis?: Shares of ADXS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.
How much money does Advaxis make?: Advaxis (NASDAQ:ADXS) has a market capitalization of $0.00 and generates $3.24 million in revenue each year. The company earns $-17.86 million in net income (profit) each year or ($0.10) on an earnings per share basis.
How can I contact Advaxis?: Advaxis' mailing address is 9 DEER PARK DRIVE SUITE K-1, MONMOUTH JUNCTION NJ, 08852. The official website for Advaxis is www.advaxis.com. The company can be reached via phone at 609 452 9813, via email at ir@advaxis.com, or via fax at 609-452-9818.

This page (NASDAQ:ADXS) was last updated on 7/3/2022 by MarketBeat.com Staff

30 Days of MarketBeat All Access for $1.00

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your Risk-Free Trial Subscription Here

MarketBeat Resources